Back to search

Article

Analysis of IgG, IgA, and IgM antibodies against SARS-CoV-2 spike protein S1 in convalescent and vaccinated patients with the Pfizer-BioNTech and CanSinoBio vaccines

2021-07-24

Abstract excerpt

The SARS-CoV-2 virus was detected for the first time in December 2019 in Wuhan, China. Currently, this virus has spread around the world, and new variants have emerged. This new pandemic virus provoked the rapid development of diagnostic tools, therapies and vaccines to control this new disease called COVID-19. Antibody detection by ELISA has been broadly used to recognize the number of persons infected with this...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5e1e7497-e21e-56e1-8ca9-aa5ca2ac6a45
DOI
10.22541/au.162713826.67558372/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Analysis of IgG, IgA, and IgM antibodies against SARS-CoV-2 spike protein S1 in convalescent and vaccinated patients with the Pfizer-BioNTech and CanSinoBio vaccinesDOI 10.22541/au.162713826.67558372/v1
Differences in the concentration of anti-SARS-CoV-2 IgG antibodies post-COVID-19 recovery or post-vaccinationSemantic proximity
Emergency Response for Evaluating SARS-CoV-2 Immune Status, Seroprevalence and Convalescent Plasma in ArgentinaSemantic proximity
The COVID-19 pandemic: viral variants and vaccine efficacySemantic proximity
SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA or vector-based vaccination in the general Dutch population show distinct kineticsSemantic proximity
Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S VaccinesSemantic proximity
Specific long‐term changes in anti‐SARS‐CoV‐2 IgG modifications and antibody functions in mRNA, adenovector, and protein subunit vaccinesSemantic proximity
Persistent Levels of Anti-SARS-CoV-2 IgM Antibody Measured by an In-house ELISA in a Convalescent Latin Population Positively Correlate with the Neutralizing Percentages to Several Variants of ConcernSemantic proximity
Development of in-house, indirect ELISAs for the detection of SARS-CoV-2 spike protein-associated serology in COVID-19 patients in PanamaSemantic proximity
Quantifying post-vaccination protective anti-SARS-CoV-2 IgG antibodies in blood and saliva with a fully automated, high throughput digital immunoassaySemantic proximity
Quantitative measurement of IgG to SARS-CoV-2 proteins using ImmunoCAPSemantic proximity
Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2Semantic proximity
Mass-Standardised Quantitative Measurements of the Antibody Levels for SARS-CoV-2 beyond Correlates of Protection and ClearanceSemantic proximity
Select a neighboring publication to make it the new centre.